{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T17:55:38Z","timestamp":1781978138114,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04738-z","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T02:47:20Z","timestamp":1760928440000},"page":"4383-4399","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Integrated computational-experimental pipeline for CHK1 inhibitor discovery: structure-based identification of novel chemotypes with anticancer activity"],"prefix":"10.1007","volume":"399","author":[{"given":"Dhanushya","family":"Gopal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasa","family":"Pacharla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal Arvind","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelin Preetha","family":"Sathiyanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5088-9683","authenticated-orcid":false,"given":"Jaikanth","family":"Chandrasekaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"4738_CR1","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.breast.2014.02.004","volume":"23","author":"L Albiges","year":"2014","unstructured":"Albiges L, Goubar A, Scott V, Vicier C, Lefebvre C, Alsafadi S, Commo F, Saghatchian M, Lazar V, Dessen P, Delaloge S, Andre F, Quidville V (2014) Chk1 As A New Therapeutic Target In Triple-Negative Breast Cancer. Breast 23:250\u2013258","journal-title":"Breast"},{"key":"4738_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ceb.2007.02.009","volume":"19","author":"J Bartek","year":"2007","unstructured":"Bartek J, Lukas J (2007) DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 19:238\u2013245","journal-title":"Curr Opin Cell Biol"},{"key":"4738_CR3","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1038\/nrm1493","volume":"5","author":"J Bartek","year":"2004","unstructured":"Bartek J, Lukas C, Lukas J (2004) Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 5:792\u2013804","journal-title":"Nat Rev Mol Cell Biol"},{"key":"4738_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2024.138595","volume":"1313","author":"T Benlatreche","year":"2024","unstructured":"Benlatreche T, Mokrani EH, Zerizer MA, Bensouici C, Golhen S, Zouchoune B, D\u00e9n\u00e8s G, Merazig H (2024) Synthesis, crystal structure, in vitro anticholinesterase activity, molecular docking and DFT investigation of three 1,10-phenanthroline-tin(IV) complexes. J Mol Struct 1313:138595","journal-title":"J Mol Struct"},{"key":"4738_CR5","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2174\/1573409916666200213124929","volume":"17","author":"I Boulhissa","year":"2021","unstructured":"Boulhissa I, Chikhi A, Bensegueni A, Ghattas MA, Mokrani EH, Alrawashdeh S, Obaid DEE (2021) Investigation of new inhibitors of Udp-N-acetylglucosamine enolpyruvyl transferase (Mura) by virtual screening with antibacterial assessment. Current Computer-Aided Drug Design 17:214\u2013224","journal-title":"Current Computer-Aided Drug Design"},{"key":"4738_CR6","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1200\/jco.2010.28.15_suppl.3062","volume":"28","author":"N Brega","year":"2010","unstructured":"Brega N, Mcarthur GA, Britten C, Wong SG, Wang E, Wilner KD, Blasina A, Schwartz GK, Gallo J, Tse AN (2010) Phase I clinical trial of Gemcitabine (Gem) in combination with Pf-00477736 (Pf-736), a selective inhibitor of Chk1 kinase. J Clin Oncol 28:3062\u20133062","journal-title":"J Clin Oncol"},{"key":"4738_CR7","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.cllc.2021.04.005","volume":"22","author":"LA Byers","year":"2021","unstructured":"Byers LA, Navarro A, Schaefer E, Johnson M, Ozguroglu M, Han JY, Bondarenko I, Cicin I, Dragnev KH, Abel A, Wang X, Mcneely S, Hynes S, Lin AB, Forster M (2021) A phase II trial of prexasertib (Ly2606368) in patients with extensive-stage small-cell lung cancer. Clin Lung Cancer 22:531\u2013540","journal-title":"Clin Lung Cancer"},{"key":"4738_CR8","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, U KM, Staten AM, Pazdur R (2002) Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res\u00a08:935\u201342"},{"key":"4738_CR9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1089\/adt.2015.674","volume":"14","author":"JL Dahlin","year":"2016","unstructured":"Dahlin JL, Walters MA (2016) How to triage pains-full research. Assay Drug Dev Technol 14:168\u2013174","journal-title":"Assay Drug Dev Technol"},{"key":"4738_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/nrc3916","volume":"15","author":"H Gaillard","year":"2015","unstructured":"Gaillard H, Garcia-Muse T, Aguilera A (2015) Replication stress and cancer. Nat Rev Cancer 15:276\u2013289","journal-title":"Nat Rev Cancer"},{"key":"4738_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph15050646","author":"D Giordano","year":"2022","unstructured":"Giordano D, Biancaniello C, Argenio MA, Facchiano A (2022) Drug design by pharmacophore and virtual screening approach. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph15050646","journal-title":"Pharmaceuticals (Basel)"},{"key":"4738_CR12","doi-asserted-by":"crossref","unstructured":"Guendouze A, Mokrani EH, Benslama O, Lekmine S (2024) Exploring the potential of avenanthramides and their analogues as a-glucosidase inhibitors for type 2 diabetes treatment utilizing virtual screening, molecular dynamics, and drug-likeness predictions. Letters In Drug Design & Discovery\u00a021:3858\u20133871","DOI":"10.2174\/0115701808306787240709073814"},{"key":"4738_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.biopha.2016.01.031","volume":"78","author":"F Guo","year":"2016","unstructured":"Guo F, Chen H, Chang J, Zhang L (2016) Mutation R273h confers P53 a stimulating effect on the Igf-1r-Akt pathway via mir-30a suppression in breast cancer. Biomed Pharmacother 78:335\u2013341","journal-title":"Biomed Pharmacother"},{"key":"4738_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1021\/acs.jcim.0c01354","volume":"61","author":"H Guterres","year":"2021","unstructured":"Guterres H, Park SJ, Jiang W, Im W (2021) Ligand-binding-site refinement to generate reliable holo protein structure conformations from apo structures. J Chem Inf Model 61:535\u2013546","journal-title":"J Chem Inf Model"},{"key":"4738_CR15","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1021\/jm030644s","volume":"47","author":"TA Halgren","year":"2004","unstructured":"Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750\u20131759","journal-title":"J Med Chem"},{"key":"4738_CR16","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-23-2005","volume":"29","author":"BM Huffman","year":"2023","unstructured":"Huffman BM, Feng H, Parmar K, Wang J, Kapner KS, Kochupurakkal B, Martignetti DB, Sadatrezaei G, Abrams TA, Biller LH, Giannakis M, Ng K, Patel AK, Perez KJ, Singh H, Rubinson DA, Schlechter BL, Andrews E, Hannigan AM, Dunwell S, Getchell Z, Raghavan S, Wolpin BM, Fortier C, D\u2019andrea AD, Aguirre AJ, Shapiro GI, Cleary JM (2023) A phase I expansion cohort study evaluating the safety and efficacy of the Chk1 inhibitor Ly2880070 with low-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 29:5047\u20135056","journal-title":"Clin Cancer Res"},{"key":"4738_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2024.100185","volume":"22","author":"K Jiang","year":"2024","unstructured":"Jiang K, Deng M, Du W, Liu T, Li J, Zhou Y (2024) Functions and inhibitors of Chk1 in cancer therapy. Med Drug Discov 22:100185","journal-title":"Med Drug Discov"},{"key":"4738_CR18","unstructured":"Jin X,\u00a0 Han J (2010) K-means clustering. In: Sammut C. & Webb, G. I. (Eds.) Encyclopedia Of Machine Learning. Boston, Ma: Springer Us"},{"key":"4738_CR19","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1074\/jbc.M116.765883","volume":"292","author":"MG Kemp","year":"2017","unstructured":"Kemp MG, Spandau DF, Simman R, Travers JB (2017) Insulin-like growth factor 1 receptor signaling is required for optimal Atr-Chk1 kinase signaling in ultraviolet B (Uvb)-irradiated human keratinocytes. J Biol Chem 292:1231\u20131239","journal-title":"J Biol Chem"},{"key":"4738_CR20","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.drudis.2021.01.008","volume":"26","author":"SR Khan","year":"2021","unstructured":"Khan SR, Al Rijjal D, Piro A, Wheeler MB (2021) Integration of AI and traditional medicine in drug discovery. Drug Discov Today 26:982\u2013992","journal-title":"Drug Discov Today"},{"key":"4738_CR21","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41416-023-02279-x","volume":"129","author":"R Kristeleit","year":"2023","unstructured":"Kristeleit R, Plummer R, Jones R, Carter L, Blagden S, Sarker D, Arkenau T, Evans TRJ, Danson S, Symeonides SN, Veal GJ, Klencke BJ, Kowalski MM, Banerji U (2023) A phase 1\/2 trial of Sra737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. Br J Cancer 129:38\u201345","journal-title":"Br J Cancer"},{"key":"4738_CR22","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547\u2013566","journal-title":"Nat Rev Drug Discov"},{"key":"4738_CR23","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1038\/sj.bjc.6605335","volume":"101","author":"LY Lim","year":"2009","unstructured":"Lim LY, Vidnovic N, Ellisen LW, Leong CO (2009) Mutant P53 mediates survival of breast cancer cells. Br J Cancer 101:1606\u20131612","journal-title":"Br J Cancer"},{"key":"4738_CR24","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","volume":"14","author":"Q Liu","year":"2000","unstructured":"Liu Q, Guntuku S, Cui XS, Matsuoka S, Cortez D, Tamai K, Luo G, Carattini-Rivera S, Demayo F, Bradley A, Donehower LA, Elledge SJ (2000) Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M Dna damage checkpoint. Genes Dev 14:1448\u20131459","journal-title":"Genes Dev"},{"key":"4738_CR25","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1074\/mcp.M700006-MCP200","volume":"6","author":"J Madoz-Gurpide","year":"2007","unstructured":"Madoz-Gurpide J, Canamero M, Sanchez L, Solano J, Alfonso P, Casal JI (2007) A proteomics analysis of cell signaling alterations in colorectal cancer. Mol Cell Proteomics 6:2150\u20132164","journal-title":"Mol Cell Proteomics"},{"key":"4738_CR26","doi-asserted-by":"publisher","DOI":"10.21105\/joss.00861","volume":"3","author":"L Mcinnes","year":"2018","unstructured":"Mcinnes L, Healy J, Saul N, Grossberger L (2018) Umap: uniform manifold approximation and projection. J Open Source Softw 3:861","journal-title":"J Open Source Softw"},{"key":"4738_CR27","doi-asserted-by":"publisher","first-page":"398","DOI":"10.17776\/csj.1063966","volume":"43","author":"EH Mokran\u0131","year":"2022","unstructured":"Mokran\u0131 EH, Abdelaz\u0131z A, Akakba N, Ten\u0131ou S, Demmak RG, Benseguen\u0131 A (2022) Molecular docking and drug-likeness prediction of new potent tubulin colchicine binding site inhibitors for potential antitumor drug. Cumhur Sci J 43:398\u2013403","journal-title":"Cumhur Sci J"},{"key":"4738_CR28","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1080\/07391102.2024.2305316","volume":"43","author":"R Muthuraj","year":"2025","unstructured":"Muthuraj R, Gopal D, Ahmed I, Chandrasekaran J (2025) Insightful T-sne guided exploration spotlighting Palbociclib and Ribociclib analogues as novel Wee1 kinase inhibitory candidates. J Biomol Struct Dyn 43:4716\u20134728","journal-title":"J Biomol Struct Dyn"},{"key":"4738_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010022","author":"SK Niazi","year":"2023","unstructured":"Niazi SK, Mariam Z (2023) Computer-aided drug design and drug discovery: a prospective analysis. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph17010022","journal-title":"Pharmaceuticals (Basel)"},{"key":"4738_CR30","doi-asserted-by":"crossref","unstructured":"Oluwafemi Shittu B, Okoye O, Olajuyigbe Olakunle J (2024) Advances in computational methods for drug design: A revolution in pharmaceutical development. Integr Biomed Res\u00a0(Journal Of Angiotherapy)\u00a08","DOI":"10.25163\/angiotherapy.879775"},{"key":"4738_CR31","doi-asserted-by":"publisher","first-page":"8328","DOI":"10.1021\/jm2007326","volume":"54","author":"JC Reader","year":"2011","unstructured":"Reader JC, Matthews TP, Klair S, Cheung KM, Scanlon J, Proisy N, Addison G, Ellard J, Piton N, Taylor S, Cherry M, Fisher M, Boxall K, Burns S, Walton MI, Westwood IM, Hayes A, Eve P, Valenti M, De Haven Brandon A, Box G, Van Montfort RL, Williams DH, Aherne GW, Raynaud FI, Eccles SA, Garrett MD, Collins I (2011) Structure-guided evolution of potent and selective Chk1 inhibitors through scaffold morphing. J Med Chem 54:8328\u20138342","journal-title":"J Med Chem"},{"key":"4738_CR32","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1021\/ci100050t","volume":"50","author":"D Rogers","year":"2010","unstructured":"Rogers D, Hahn M (2010) Extended-connectivity fingerprints. J Chem Inf Model 50:742\u2013754","journal-title":"J Chem Inf Model"},{"key":"4738_CR33","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.277.5331.1497","volume":"277","author":"Y Sanchez","year":"1997","unstructured":"Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, Elledge SJ (1997) Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science 277:1497\u20131501","journal-title":"Science"},{"key":"4738_CR34","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1200\/JCO.2001.19.8.2319","volume":"19","author":"EA Sausville","year":"2001","unstructured":"Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM (2001) Phase I trial of 72-hour continuous infusion Ucn-01 in patients with refractory neoplasms. J Clin Oncol 19:2319\u20132333","journal-title":"J Clin Oncol"},{"key":"4738_CR35","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s00280-013-2234-6","volume":"72","author":"T Seto","year":"2013","unstructured":"Seto T, Esaki T, Hirai F, Arita S, Nosaki K, Makiyama A, Kometani T, Fujimoto C, Hamatake M, Takeoka H, Agbo F, Shi X (2013) Phase I, dose-escalation study of Azd7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours. Cancer Chemother Pharmacol 72:619\u2013627","journal-title":"Cancer Chemother Pharmacol"},{"key":"4738_CR36","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S1535-6108(02)00102-2","volume":"2","author":"CJ Sherr","year":"2002","unstructured":"Sherr CJ, Mccormick F (2002) The Rb and P53 pathways in cancer. Cancer Cell 2:103\u2013112","journal-title":"Cancer Cell"},{"key":"4738_CR37","doi-asserted-by":"crossref","unstructured":"Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. (2014) Computational methods in drug discovery. Pharmacol Rev 66:334\u2013395","DOI":"10.1124\/pr.112.007336"},{"key":"4738_CR38","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-03-0757","volume":"10","author":"V Sriuranpong","year":"2004","unstructured":"Sriuranpong V, Mutirangura A, Gillespie JW, Patel V, Amornphimoltham P, Molinolo AA, Kerekhanjanarong V, Supanakorn S, Supiyaphun P, Rangdaeng S, Voravud N, Gutkind JS (2004) Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary dna microarrays. Clin Cancer Res 10:4944\u20134958","journal-title":"Clin Cancer Res"},{"key":"4738_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.690306","volume":"9","author":"A Turdo","year":"2021","unstructured":"Turdo A, D\u2019accardo C, Glaviano A, Porcelli G, Colarossi C, Colarossi L, Mare M, Faldetta N, Modica C, Pistone G, Bongiorno MR, Todaro M, Stassi G (2021) Targeting phosphatases and kinases: how to checkmate cancer. Front Cell Dev Biol 9:690306","journal-title":"Front Cell Dev Biol"},{"key":"4738_CR40","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1158\/0008-5472.CAN-06-3545","volume":"67","author":"L Verlinden","year":"2007","unstructured":"Verlinden L, Vanden Bempt I, Eelen G, Drijkoningen M, Verlinden I, Marchal K, De Wolf-Peeters C, Christiaens MR, Michiels L, Bouillon R, Verstuyf A (2007) The E2f-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor \/progesterone receptor \/Her-2 breast carcinomas. Cancer Res 67:6574\u20136581","journal-title":"Cancer Res"},{"key":"4738_CR41","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.leukres.2017.09.005","volume":"61","author":"JA Webster","year":"2017","unstructured":"Webster JA, Tibes R, Morris L, Blackford AL, Litzow M, Patnaik M, Rosner GL, Gojo I, Kinders R, Wang L, Doyle LA, Huntoon CJ, Karnitz LM, Kaufmann SH, Karp JE, Smith BD (2017) Randomized phase II trial of cytosine arabinoside with and without the Chk1 inhibitor Mk-8776 in relapsed and refractory acute myeloid leukemia. Leuk Res 61:108\u2013116","journal-title":"Leuk Res"},{"key":"4738_CR42","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.lungcan.2017.03.001","volume":"108","author":"T Wehler","year":"2017","unstructured":"Wehler T, Thomas M, Schumann C, Bosch-Barrera J, Vinolas Segarra N, Dickgreber NJ, Dalhoff K, Sebastian M, Corral Jaime J, Alonso M, Hynes SM, Lin J, Hurt K, Bence Lin A, Calvo E, Paz-Ares L (2017) A randomized, phase 2 evaluation of the Chk1 inhibitor, Ly2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. Lung Cancer 108:212\u2013216","journal-title":"Lung Cancer"},{"key":"4738_CR43","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/onc.2012.121","volume":"32","author":"J Xu","year":"2013","unstructured":"Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, Xie X, Zhou C, Lu W (2013) Suppressed Mir-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 32:976\u2013987","journal-title":"Oncogene"},{"key":"4738_CR44","first-page":"1080","volume":"35","author":"H Yao","year":"2010","unstructured":"Yao H, Yang Z, Li Y (2010) Expression of Checkpoint kinase 1 and Polo-like kinase 1 and its clinicopathological significance in benign and malignant lesions of the stomach. Zhong Nan Da Xue Xue Bao Yi Xue Ban 35:1080\u20131084","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"4738_CR45","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1002\/ijc.28226","volume":"134","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Hunter T (2014) Roles of Chk1 in cell biology and cancer therapy. Int J Cancer 134:1013\u20131023","journal-title":"Int J Cancer"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04738-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04738-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T08:00:56Z","timestamp":1772006456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04738-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4738"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04738-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\u00a0"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}